Krystal Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Krystal Biotech wird ein jährliches Gewinn- und Umsatzwachstum von 37% bzw. 34.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 36.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.4% betragen.

Wichtige Informationen

37.0%

Wachstumsrate der Gewinne

36.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.3%
Wachstumsrate der Einnahmen	34.1%
Zukünftige Eigenkapitalrendite	18.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Sep 06

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Aug 08

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

May 17

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Jan 30

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20

Krystal Biotech: The Future Looks More And More Derisked

Feb 21

Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications

Nov 30

Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

Sep 27

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Sep 25

Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

Jun 17

Krystal Biotech EPS misses by $0.16

May 10

Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB

Apr 26

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Mar 02

Krystal Biotech secures $125 capital via equity raise

Feb 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:KRYS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	603	249	345	N/A	7
12/31/2025	426	144	240	166	9
12/31/2024	266	63	130	105	10
3/31/2024	96	57	-54	-47	N/A
12/31/2023	51	11	-101	-89	N/A
9/30/2023	9	-30	-119	-104	N/A
6/30/2023	N/A	-140	-130	-102	N/A
3/31/2023	N/A	-135	-152	-111	N/A
12/31/2022	N/A	-140	-154	-101	N/A
9/30/2022	N/A	-130	-188	-99	N/A
6/30/2022	N/A	-115	-182	-87	N/A
3/31/2022	N/A	-104	-137	-54	N/A
12/31/2021	N/A	-70	-116	-48	N/A
9/30/2021	N/A	-58	-70	-35	N/A
6/30/2021	N/A	-52	-52	-35	N/A
3/31/2021	N/A	-43	-45	-30	N/A
12/31/2020	N/A	-32	-41	-26	N/A
9/30/2020	N/A	-27	-35	-25	N/A
6/30/2020	N/A	-22	-29	-23	N/A
3/31/2020	N/A	-20	-28	-22	N/A
12/31/2019	N/A	-19	-25	-19	N/A
9/30/2019	N/A	-17	-21	-15	N/A
6/30/2019	N/A	-16	-18	-13	N/A
3/31/2019	N/A	-13	-14	-10	N/A
12/31/2018	N/A	-11	-12	-9	N/A
9/30/2018	N/A	-9	-9	-8	N/A
6/30/2018	N/A	-11	-7	-7	N/A
3/31/2018	N/A	-10	-6	-6	N/A
12/31/2017	N/A	-8	N/A	-4	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KRYSDas prognostizierte Gewinnwachstum (37% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: KRYSDie Erträge des Unternehmens (37% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: KRYSEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: KRYSDie Einnahmen des Unternehmens (34.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: KRYSDie Einnahmen des Unternehmens (34.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: KRYSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.4%).

Krystal Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 16%

Consensus EPS estimates increase by 11%

Price target increased by 14% to US$176

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates decrease by 11%, EPS upgraded

Recent updates

Founder notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Consensus EPS estimates increase by 16%

Krystal Biotech, Inc. to Report Q1, 2024 Results on May 06, 2024

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Consensus EPS estimates increase by 11%

Krystal Biotech, Inc., Annual General Meeting, May 17, 2024

Founder notifies of intention to sell stock

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Price target increased by 14% to US$176

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Krystal Biotech, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Krystal Biotech: Ready For Launch

Executive VP & Chief Accounting Officer notifies of intention to sell stock

Krystal Biotech Receives Permanent J-Code (J3401) for VYJUVEK®

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Founder notifies of intention to sell stock

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Consensus revenue estimates decrease by 11%, EPS upgraded

Krystal Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for KB408 for Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Founder notifies of intention to sell stock

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Consensus revenue estimates increase by 28%

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Price target increased by 8.8% to US$148

Krystal Biotech, Inc. Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Krystal Biotech, Inc.(NasdaqGM:KRYS) dropped from Russell Small Cap Comp Value Index

Lead Independent Director recently sold US$6.4m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$813k worth of stock

Founder recently sold US$2.9m worth of stock

Founder notifies of intention to sell stock

FDA Approves New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'

Consensus revenue estimates increase by 28%

Krystal Biotech, Inc. announced that it expects to receive $159.999933 million in funding from Avoro Capital Advisors LLC, Redmile Group, LLC, Braidwell LP, Frazier Life Sciences Management, LP, Lighthouse Investment Partners, LLC

Executive VP & Chief Accounting Officer notifies of intention to sell stock

No longer forecast to breakeven

Krystal Biotech, Inc. Receives FDA Approval for the First-Ever Redosable Gene Therapy, Vyjuvek™? (Beremagenegeperpavec-Svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Price target increased by 7.2% to US$115

No longer forecast to breakeven

Founder notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Independent Director recently sold US$3.3m worth of stock

Forecast breakeven date moved forward to 2024

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Founder notifies of intention to sell stock

Krystal Biotech, Inc. Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

Forecast to breakeven in 2025

Krystal Biotech, Inc. Announces New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

US Food and Drug Administration Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

Krystal Biotech: Solid Performance, Let's Keep Holding

Consensus revenue estimates fall by 90%

Founder notifies of intention to sell stock

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Krystal Biotech, Inc. Receives Fda Acceptance of Kb407 Ind Application for Cystic Fibrosis Clinical Trial

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa